EP4739352A1 - Menschliche therapie mit neuen prokaryotischen spannungsgesteuerten natriumkanälen - Google Patents

Menschliche therapie mit neuen prokaryotischen spannungsgesteuerten natriumkanälen

Info

Publication number
EP4739352A1
EP4739352A1 EP24836630.4A EP24836630A EP4739352A1 EP 4739352 A1 EP4739352 A1 EP 4739352A1 EP 24836630 A EP24836630 A EP 24836630A EP 4739352 A1 EP4739352 A1 EP 4739352A1
Authority
EP
European Patent Office
Prior art keywords
subject
promoter
heart failure
vector
bacnav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24836630.4A
Other languages
English (en)
French (fr)
Inventor
Nenad Bursac
Tianyau WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of EP4739352A1 publication Critical patent/EP4739352A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP24836630.4A 2023-07-05 2024-07-05 Menschliche therapie mit neuen prokaryotischen spannungsgesteuerten natriumkanälen Pending EP4739352A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363512038P 2023-07-05 2023-07-05
PCT/US2024/036948 WO2025010423A1 (en) 2023-07-05 2024-07-05 Human therapy utilizing novel prokaryotic voltage gated sodium channels

Publications (1)

Publication Number Publication Date
EP4739352A1 true EP4739352A1 (de) 2026-05-13

Family

ID=94172297

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24836630.4A Pending EP4739352A1 (de) 2023-07-05 2024-07-05 Menschliche therapie mit neuen prokaryotischen spannungsgesteuerten natriumkanälen

Country Status (2)

Country Link
EP (1) EP4739352A1 (de)
WO (1) WO2025010423A1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975645A1 (en) * 2016-08-05 2018-02-05 The Governors Of The University Of Alberta Systems and methods of selecting compounds with reduced risk of cardiotoxicity using cardiac sodium ion channel models
EP4045093A4 (de) * 2019-10-14 2024-02-07 Duke University Zusammensetzungen mit neuen prokaryotischen natriumkanälen und zugehörige verfahren

Also Published As

Publication number Publication date
WO2025010423A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
Biggar et al. Duchenne muscular dystrophy: current knowledge, treatment, and future prospects
JP2010516252A (ja) 筋鞘にｎＮＯＳを回復させる合成ミニ／ミクロジストロフィン遺伝子
CN116406297A (zh) 治疗心脏疾患和充血性心力衰竭以及施用aav载体的方法
ES2320975T3 (es) Mutante plb dominante negativo para su utilizacion en el tratamiento de enfermedades cardiacas.
HK1222884A1 (zh) 用於治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法
CN101977632A (zh) 用于增强病毒载体于心肌中的摄取的组合物
US20170252462A1 (en) Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
WO2025010423A1 (en) Human therapy utilizing novel prokaryotic voltage gated sodium channels
US8445454B2 (en) Use on minicircle vectors for cardiac gene therapy
US20230024301A1 (en) Treatment of diseases caused by frame shift mutations
JP2025523953A (ja) 肢帯型筋ジストロフィーのためのａｕｆ１遺伝子療法
KR20190050277A (ko) 허혈성 심혈관 질환의 치료용 또는 예방용 약학 조성물
JP7541003B2 (ja) 心不全の治療及び予防における使用のためのリラキシン受容体１
Sun et al. Prolonged hypotensive effect of human tissue kallikrein gene delivery and recombinant enzyme administration in spontaneous hypertension rats
CN111138549A (zh) 一种抗肌萎缩融合蛋白mUp113
Wu Optimization and Evaluation of Engineered Prokaryotic Sodium Channel Gene Therapy for Heart Failure and Cardiac Arrhythmias
US20240058475A1 (en) Methods and compositions for treating muscular dystrophy
AU2021417194A1 (en) Methods and compositions for treating muscular dystrophy
Betts Exon skipping peptide-pmos for correction of dystrophin in mouse models of duchenne muscular dystrophy
Bish Myostatin regulation and function in the heart
TW202227628A (zh) 用於治療肌肉萎縮症之方法及組合物
Pacak Gene delivery strategies for the treatment of cardiac and skeletal muscle in murine models of muscular dystrophy
HK1056316B (en) Dominant negative plb mutant for use in treating cardiac disease

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR